Literature DB >> 15061210

Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery.

D P Kontoyiannis1, G P Bodey, H Hanna, R Hachem, M Boktour, E Girgaway, M Mardani, I I Raad.   

Abstract

Factors associated with failure of antifungal therapy were examined in 42 cancer patients with fusariosis (1987-1997). Thirty-six patients (86%) had leukemia and 39 (93%) were neutropenic. Disseminated infection was the most common presentation. The majority (83%) received amphotericin B-based therapy. Thirty patients (71%) failed therapy. No patient with persistent neutropenia responded.

Entities:  

Mesh:

Year:  2004        PMID: 15061210     DOI: 10.1080/1042819031000149386

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  17 in total

1.  Does granulocyte transfusion play a role in the multidisciplinary treatment of invasive mycosis?

Authors:  Simone Cesaro; Piero Marson
Journal:  Support Care Cancer       Date:  2006-10-12       Impact factor: 3.603

2.  Pentamidine is active in a neutropenic murine model of acute invasive pulmonary fusariosis.

Authors:  Michail S Lionakis; Georgios Chamilos; Russell E Lewis; Nathan P Wiederhold; Issam I Raad; George Samonis; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.

Authors:  A J Ullmann; O A Cornely; A Burchardt; R Hachem; D P Kontoyiannis; K Töpelt; R Courtney; D Wexler; G Krishna; M Martinho; G Corcoran; I Raad
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Time of incubation for antifungal susceptibility testing of Aspergillus fumigatus: can MIC values be obtained at 24 hours?

Authors:  Juan Luis Rodriguez-Tudela; Laura Alcazar-Fuoli; Ana Alastruey-Izquierdo; Araceli Monzon; Emilia Mellado; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

Review 5.  Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.

Authors:  Frederic Lamoth; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 6.  Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Zahida Bhatti; Aasma Shaukat; Nikolaos G Almyroudis; Brahm H Segal
Journal:  Mycopathologia       Date:  2006-07       Impact factor: 2.574

Review 7.  Recent developments in the management of invasive fungal infections in patients with oncohematological diseases.

Authors:  Markus Ruhnke; Stefan Schwartz
Journal:  Ther Adv Hematol       Date:  2016-07-01

8.  Disseminated amphotericin-resistant fusariosis in acute leukemia patients: report of two cases.

Authors:  Graziella Hanna Pereira; Derlene Attili de Angelis; Roosecelis Araujo Brasil; Marilena dos Anjos Martins; Dulcilena de Matos Castro e Silva; Maria Walderez Szeszs; Marcia de Souza Carvalho Melhem
Journal:  Mycopathologia       Date:  2012-10-18       Impact factor: 2.574

9.  Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.

Authors:  Laura Alcazar-Fuoli; Emilia Mellado; Ana Alastruey-Izquierdo; Manuel Cuenca-Estrella; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

10.  Combination antifungal therapy: from bench to bedside.

Authors:  Baldeep Wirk; John R Wingard
Journal:  Curr Infect Dis Rep       Date:  2008-11       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.